As such, loss-of-function in PTEN in conjunction with amplifications and activating mutations in the PI3K pathway can synergise to promote higher-grade, more invasive PCa and tumour recurrence following treatment (Robinson et al. 2015). Here, PTEN is linked to neoplasm.